Interferon-beta1b in multiple sclerosis.

Expert Rev Neurother 2007 Mar;7(3):227-39

Julius-Maximilians University, Department of Neurology, Josef-Schneider-Str. 11, D-97080 W├╝rzburg, Germany.

In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. We then summarize current knowledge about the biochemical structure of IFN-beta(1b), as well as pharmacokinetics and pharmacodynamics, including data on putative mechanisms underlying therapeutic as well as adverse effects. Furthermore, a critical review of ongoing and recently published clinical trials investigating IFN-beta(1b) in multiple sclerosis will be provided. Main topics are: trials investigating IFN-beta(1b) after a first clinical event, at higher dosages or in comparison to once-weekly subcutaneous IFN-beta(1a) injections, 16 years of long-term follow-up, IFN-beta(1b) in Japanese patients, the role of neutralizing antibodies, biomarkers for the prediction of therapy response, IFN-beta(1b) and pregnancy, and IFN-beta(1b) treatment of children with multiple sclerosis. Finally, we discuss how novel drugs, especially monoclonal antibodies and orally administered immunosuppressants, might soon challenge the position of this well-established agent on the multiple sclerosis therapeutics market.

Download full-text PDF

Source
http://dx.doi.org/10.1586/14737175.7.3.227DOI Listing
March 2007
2 Reads

Publication Analysis

Top Keywords

multiple sclerosis
24
ifn-beta1b
8
investigating ifn-beta1b
8
trials investigating
8
sclerosis
6
multiple
5
higher dosages
4
dosages comparison
4
event higher
4
comparison once-weekly
4
topics trials
4
ifn-beta1b clinical
4
clinical event
4
once-weekly subcutaneous
4
long-term follow-up
4
follow-up ifn-beta1b
4
years long-term
4
injections years
4
subcutaneous ifn-beta1a
4
ifn-beta1a injections
4

References

(Supplied by CrossRef)

Compston et al.
Lancet 2002

Pugliatti et al.
Eur. J. Neurol. 2006

Sadovnick et al.
Can. J. Neurol. Sci. 1993

Bronnum-Hansen et al.
Int. MS J. 2006

Frohman et al.
N. Engl. J. Med. 2006

Minden et al.
Mult. Scler. 2006

Ramsaransing et al.
Acta Neurol. Scand. 2006

Rovaris et al.
Lancet Neurol. 2006

Montalban et al.
Curr. Opin. Neurol. 2005

Thompson et al.
Ann. Neurol. 2000

Gayou et al.
J. Neurol. Neurosurg. Psychiatr. 1997

Similar Publications